Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.300
-0.070 (-5.11%)
Apr 29, 2026, 10:01 AM EDT - Market open

Cardiol Therapeutics Cash Flow Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2017
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2017
Net Income
-33.82-36.68-28.13-30.93-31.64
Upgrade
Depreciation & Amortization
0.10.370.250.220.22
Upgrade
Asset Writedown & Restructuring Costs
---1.360.08
Upgrade
Stock-Based Compensation
10.714.284.175.5412.61
Upgrade
Other Operating Activities
-0.11-2.1-0.93-9.15-4.89
Upgrade
Change in Accounts Receivable
0.040.040.07-0.14-0.06
Upgrade
Change in Inventory
----0.02
Upgrade
Change in Accounts Payable
0.26-1.06-1.294.472.39
Upgrade
Change in Other Net Operating Assets
-1.040.090.681.42-2.27
Upgrade
Operating Cash Flow
-23.85-25.06-25.18-27.22-23.54
Upgrade
Capital Expenditures
-0.02-0.02-0.06-0.07-0.01
Upgrade
Investing Cash Flow
-0.02-0.02-0.06-0.07-0.01
Upgrade
Long-Term Debt Repaid
-0.06-0.04-0.06-0.05-0.05
Upgrade
Net Debt Issued (Repaid)
-0.06-0.04-0.06-0.05-0.05
Upgrade
Issuance of Common Stock
16.0721.53--98.72
Upgrade
Other Financing Activities
-0.48-2.65---5.23
Upgrade
Financing Cash Flow
15.5418.84-0.06-0.0593.44
Upgrade
Foreign Exchange Rate Adjustments
-0.821.890.762.92-0.01
Upgrade
Net Cash Flow
-9.16-4.35-24.54-24.4369.87
Upgrade
Free Cash Flow
-23.88-25.08-25.24-27.3-23.55
Upgrade
Free Cash Flow Margin
-----29904.22%
Upgrade
Free Cash Flow Per Share
-0.28-0.35-0.39-0.44-0.55
Upgrade
Levered Free Cash Flow
-13.03-11.71-14.99-20.64-4.61
Upgrade
Unlevered Free Cash Flow
-13.03-11.71-14.99-20.64-4.61
Upgrade
Change in Working Capital
-0.73-0.93-0.555.750.08
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.